Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Strony

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
JAMA|February 7, 2002
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent interventionJ Conor O'Shea, Christopher E Buller, Warren J Cantor, et al.
American Heart Journal|December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trialPierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
The American Journal of Cardiology|August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
The American Journal of Cardiology|March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
European Heart Journal. Acute Cardiovascular Care|February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trialRalf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
JAMA|February 7, 2002
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent interventionJ Conor O'Shea, Christopher E Buller, Warren J Cantor, et al.
American Heart Journal|December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trialPierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
The American Journal of Cardiology|August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.
The American Journal of Cardiology|March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
Pageof 5